Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $555.67. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $570 IDXX trades at 42× p/e, in line with its 37× p/e peer median — but our blended $445 fair value sits below the price. It's a high-confidence read. Even valued only for durable growth at sustainable margins, it's worth about $606 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 167% over what the business is worth with no growth; closing that gap needs roughly 21.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $12.52/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $553.58 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $553.88 | — | — | Hist. CAGR | high |
| graham number | 12M | $77.02 | — | — | TTM | high |
| Mgmt guidance | 12M | $526.37 | 35.9 | 14.68 | Mgmt | high |
| Peer EV/EBITDA | 12M | $108.96 | 6.2 | 19.35 | TTM | high |
| Peer P/FCF | 12M | $317.22 | 23.6 | 13.47 | TTM | high |
| Peer P/E | 12M | $487.09 | 35.9 | 13.58 | TTM | high |
| Peer P/S | 12M | $153.09 | 2.8 | 55.46 | TTM | high |
| PEG | 12M | $436.62 | 32.2 | 13.58 | TTM | high |
| residual income | 12M | $65.33 | — | — | TTM | high |
| Own P/E history | 12M | $577.39 | 42.5 | 13.58 | TTM | high |
| triangulated | 12M | $507.06 | 35.9 | 14.14 | Triangulated | high |
| Mgmt guidance | 3Y | $782.23 | 35.9 | 21.81 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $482.45 | 23.6 | 20.48 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $644.12 | 35.9 | 17.96 | Analyst | medium |
| Peer P/S | 3Y | $191.45 | 2.8 | 69.36 | guidance | medium |
| PEG | 3Y | $577.38 | 32.2 | 17.96 | Analyst | medium |
| Own P/E history | 3Y | $763.53 | 42.5 | 17.96 | Analyst | medium |
| Mgmt guidance | 5Y | $1018.67 | 35.9 | 28.40 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $638.04 | 23.6 | 27.09 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $715.97 | 35.9 | 19.96 | Analyst | high |
| Peer P/S | 5Y | $212.80 | 2.8 | 77.10 | guidance | high |
| PEG | 5Y | $641.78 | 32.2 | 19.96 | Analyst | high |
| Own P/E history | 5Y | $848.69 | 42.5 | 19.96 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.